Valneva SE: Chikungunya Vaccine Triggers Trend Reversal!
The biotech initiates a trend reversal as the WHO fears a global Chikungunya epidemic and Valneva has the suitable vaccine ready!
Reading Time: 1 minute
The biotech company Valneva has established a strong position with vaccines for infectious diseases with high unmet needs. The company already has approved vaccines against Chikungunya, Cholera, and Japanese Encephalitis (JE). In addition, research is ongoing for vaccines against Shigella, Zika, and Lyme disease. Last month, the stock was able to initiate a trend reversal after the European Medicines Agency (EMA) lifted the temporary application restriction for the Chikungunya vaccine IXCHIQ in older individuals. This restriction had...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
